CN112175911B - 经修饰的自然杀伤细胞及其用途 - Google Patents

经修饰的自然杀伤细胞及其用途 Download PDF

Info

Publication number
CN112175911B
CN112175911B CN202011087292.9A CN202011087292A CN112175911B CN 112175911 B CN112175911 B CN 112175911B CN 202011087292 A CN202011087292 A CN 202011087292A CN 112175911 B CN112175911 B CN 112175911B
Authority
CN
China
Prior art keywords
cells
cell
immune cell
mbil15
transduced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011087292.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN112175911A (zh
Inventor
达里奥·坎帕纳
大卫·舒克
今村胜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National University of Singapore
St Jude Childrens Research Hospital
Original Assignee
National University of Singapore
St Jude Childrens Research Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University of Singapore, St Jude Childrens Research Hospital filed Critical National University of Singapore
Priority to CN202011087292.9A priority Critical patent/CN112175911B/zh
Publication of CN112175911A publication Critical patent/CN112175911A/zh
Application granted granted Critical
Publication of CN112175911B publication Critical patent/CN112175911B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
CN202011087292.9A 2014-05-15 2015-05-14 经修饰的自然杀伤细胞及其用途 Active CN112175911B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011087292.9A CN112175911B (zh) 2014-05-15 2015-05-14 经修饰的自然杀伤细胞及其用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461993494P 2014-05-15 2014-05-15
US61/993,494 2014-05-15
CN202011087292.9A CN112175911B (zh) 2014-05-15 2015-05-14 经修饰的自然杀伤细胞及其用途
PCT/SG2015/050111 WO2015174928A1 (en) 2014-05-15 2015-05-14 Modified natural killer cells and uses thereof
CN201580024756.2A CN106459914B (zh) 2014-05-15 2015-05-14 经修饰的自然杀伤细胞及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580024756.2A Division CN106459914B (zh) 2014-05-15 2015-05-14 经修饰的自然杀伤细胞及其用途

Publications (2)

Publication Number Publication Date
CN112175911A CN112175911A (zh) 2021-01-05
CN112175911B true CN112175911B (zh) 2023-10-13

Family

ID=54480322

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202011087292.9A Active CN112175911B (zh) 2014-05-15 2015-05-14 经修饰的自然杀伤细胞及其用途
CN201580024756.2A Active CN106459914B (zh) 2014-05-15 2015-05-14 经修饰的自然杀伤细胞及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580024756.2A Active CN106459914B (zh) 2014-05-15 2015-05-14 经修饰的自然杀伤细胞及其用途

Country Status (12)

Country Link
US (5) US10428305B2 (enExample)
EP (2) EP3143134B1 (enExample)
JP (4) JP6694875B2 (enExample)
KR (3) KR20210014210A (enExample)
CN (2) CN112175911B (enExample)
AU (3) AU2015259877B2 (enExample)
CA (1) CA2948462A1 (enExample)
DK (1) DK3143134T3 (enExample)
ES (1) ES2839089T3 (enExample)
PT (1) PT3143134T (enExample)
SG (1) SG11201609118RA (enExample)
WO (1) WO2015174928A1 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
KR102238226B1 (ko) 2013-05-14 2021-04-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
KR102375998B1 (ko) 2014-02-14 2022-03-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 항원 수용체 및 제조방법
EP3143134B1 (en) * 2014-05-15 2020-10-28 National University of Singapore Modified natural killer cells and uses thereof
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
US10875919B2 (en) 2016-04-26 2020-12-29 Alector Llc Chimeric receptors and methods of use thereof
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
CA3023239A1 (en) 2016-05-07 2017-11-16 Celularity Inc. Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
CN110494543A (zh) 2016-10-19 2019-11-22 弗洛设计声能学公司 通过声学的亲和细胞提取
KR20240128814A (ko) 2017-01-10 2024-08-27 프레시전 인코포레이티드 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절
WO2018161026A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il15 compositions and methods for immunotherapy
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
SG11201908492PA (en) * 2017-03-27 2019-10-30 Nat Univ Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
EP3601537A4 (en) 2017-03-27 2021-01-13 National University of Singapore STIMULATING CELL LINES FOR EX VIVO EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS
CA3026892A1 (en) 2017-05-10 2018-11-15 Wellstat Immunotherapeutics, Llc Enveloped virus resistant to complement inactivation for the treatment of cancer
EP3634437A4 (en) 2017-05-19 2020-11-18 Case Western Reserve University COMPOSITIONS AND METHODS FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES
KR20220066413A (ko) 2017-12-14 2022-05-24 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
CA3083779A1 (en) 2017-12-22 2019-06-27 Fate Therapeutics, Inc. Enhanced immune effector cells and use thereof
EP3746095A4 (en) * 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
WO2019155286A2 (en) * 2018-02-09 2019-08-15 National University Of Singapore Adhesion receptor constructs and uses thereof in natural killer cell immunotherapy
CN111801348A (zh) 2018-02-09 2020-10-20 新加坡国立大学 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
WO2019157130A1 (en) * 2018-02-09 2019-08-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tethered interleukin-15 and interleukin-21
KR20200138741A (ko) 2018-04-02 2020-12-10 내셔널 유니버시티 오브 싱가포르 면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화
CN108715834B (zh) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种富含cd41+、cd81+微囊的血小板裂解液制备方法
JP7560882B2 (ja) 2018-08-29 2024-10-03 ナショナル ユニヴァーシティー オブ シンガポール 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法
JP7520818B2 (ja) * 2018-09-13 2024-07-23 ンカルタ・インコーポレイテッド 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
WO2020185698A1 (en) * 2019-03-08 2020-09-17 Research Institute At Nationwide Children's Hospital Stat3 transcriptome for designing more potent nk cells
KR20200110576A (ko) * 2019-03-15 2020-09-24 재단법인대구경북과학기술원 사이토카인 기반 면역세포 및 그의 면역 치료 용도
CN113811603B (zh) * 2019-03-15 2024-08-16 河谷细胞有限公司 重组erIL-15 NK细胞
SG11202111130SA (en) 2019-04-30 2021-11-29 Senti Biosciences Inc Chimeric receptors and methods of use thereof
US20220233593A1 (en) * 2019-06-04 2022-07-28 Nkarta, Inc. Combinations of engineered natural killer cells and engineered t cells for immunotherapy
KR20220038439A (ko) * 2019-07-31 2022-03-28 엔카르타, 인크. 자연 살해 세포의 향상된 증폭 및 세포 독성을 위한 방법 및 조성물
WO2021050789A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
WO2021054789A1 (ko) * 2019-09-18 2021-03-25 주식회사 에스엘바이젠 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도
CN113603787B (zh) * 2020-05-04 2023-05-23 英诺康生物医药科技(广州)有限公司 一种非分泌型的人白细胞介素15及应用
US20240261401A1 (en) * 2020-05-29 2024-08-08 Icell Gene Therapeutics Inc. Engineered immune cells, compositions and methods thereof
US12012458B2 (en) 2020-06-12 2024-06-18 Nkarta, Inc. Genetically modified natural killer cells for CD70-directed cancer immunotherapy
AU2021377699A1 (en) 2020-11-13 2023-06-15 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
AU2021388155A1 (en) 2020-11-25 2023-06-15 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
AU2022211438A1 (en) * 2021-01-19 2023-08-17 Obsidian Therapeutics, Inc. Tumor-infiltrating lymphocytes with membrane bound interleukin 15 and uses thereof
EP4362957A1 (en) 2021-07-01 2024-05-08 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
WO2023199961A1 (ja) * 2022-04-14 2023-10-19 第一三共株式会社 膜型サイトカイン及びｔｎｆ受容体スーパーファミリー分子の細胞内ドメインをコードするポリヌクレオチド
US20250295773A1 (en) 2022-05-10 2025-09-25 Miltenyi Biotec B.V. & Co. KG Compositions comprising il-15, il-15 receptor alpha and the intracellular signaling domain of cd2 for immune cell therapy
CA3259982A1 (en) 2022-06-30 2024-01-04 Indapta Therapeutics Inc COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS
JP2025524005A (ja) * 2022-07-22 2025-07-25 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 養子免疫療法のための亢進された機能を有するｃｄ３発現ナチュラルキラー細胞
WO2024153124A1 (zh) * 2023-01-18 2024-07-25 南京传奇生物科技有限公司 经修饰的原代t细胞及其用途
CN117467022B (zh) * 2023-09-28 2024-10-22 上海恩凯细胞技术有限公司 嵌合抗原受体及其应用
WO2025184170A1 (en) 2024-02-27 2025-09-04 Overt Bio, Inc. Methods and compositions for improving t cell function in an immunosuppressive environment
CN118406654B (zh) * 2024-04-26 2025-03-21 中国海洋大学 经修饰的nk细胞及其构建方法和应用

Family Cites Families (233)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6355476B1 (en) 1988-11-07 2002-03-12 Advanced Research And Technologyinc Nucleic acid encoding MIP-1α Lymphokine
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
AU643109B2 (en) 1990-12-14 1993-11-04 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
EP0585257A4 (en) 1991-03-28 1995-02-22 Univ Minnesota DNA AND AMINO ACID SEQUENCE SPECIFIC TO NATURAL K KILLER CELLS.
US5674704A (en) 1993-05-07 1997-10-07 Immunex Corporation Cytokine designated 4-IBB ligand
JPH09501055A (ja) 1993-07-30 1997-02-04 ユニバーシティ オブ メディシン アンド デンティストリー オブ ニュージャージー 初代リンパ球への効率的遺伝子転移
US5653977A (en) 1993-09-09 1997-08-05 Uab Research Foundation Anti-idiotypic antibody that mimics the GD2 antigen
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en) 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
DE19520729A1 (de) 1995-06-07 1996-12-12 Orpegen Pharma Gmbh Testsystem zur Erfassung der Aktivität von NK-Zellen
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US20020018783A1 (en) 1997-03-20 2002-02-14 Michel Sadelain Fusion proteins of a single chain antibody and cd28 and uses thereof
GB9713473D0 (en) 1997-06-25 1997-09-03 Celltech Therapeutics Ltd Biological products
PT1003861E (pt) 1997-08-01 2007-01-31 Schering Corp Proteínas de membrana de células de mamíferos;reagentes relacionados
GB9725764D0 (en) 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
AU741602B2 (en) 1998-02-02 2001-12-06 Johns Hopkins University School Of Medicine, The A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
DE19813759C1 (de) 1998-03-27 1999-07-15 Gsf Forschungszentrum Umwelt Verfahren zur Induktion einer durch NK-Zellen vermittelten Immunantwort
GB9809658D0 (en) 1998-05-06 1998-07-01 Celltech Therapeutics Ltd Biological products
US6361998B1 (en) 1998-06-25 2002-03-26 Hemosol Inc. Efficient culture of stem cells for the production of hemoglobin
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
JP2002541845A (ja) 1999-04-16 2002-12-10 セルテック セラピューティックス リミテッド 合成膜貫通成分
WO2001029191A1 (fr) 1999-10-21 2001-04-26 Keisuke Teshigawara Methode de culture in vitro de lymphocytes et compositions de therapie genique
JP3619853B2 (ja) 1999-11-26 2005-02-16 独立行政法人理化学研究所 ナチュラルキラー細胞の増殖方法
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
JP2002045174A (ja) 2000-07-31 2002-02-12 Inst Of Physical & Chemical Res ナチュラルキラー細胞増殖法
GB0025307D0 (en) 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
EP1334188B1 (en) 2000-11-07 2006-08-30 City of Hope Cd19-specific redirected immune cells
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20030129649A1 (en) 2001-04-24 2003-07-10 Kobilka Brian K. Conformational assays to detect binding to G protein-coupled receptors
KR100888915B1 (ko) 2001-08-15 2009-03-16 다카라 바이오 가부시키가이샤 항원특이적 세포상해성 ｔ 세포 확대배양방법
CA2457143A1 (en) * 2001-08-17 2003-02-27 Roger Williams Hospital In situ immunization
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
WO2003089616A2 (en) 2002-04-22 2003-10-30 Fred Hutchinson Cancer Research Center Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
WO2004027036A2 (en) 2002-09-19 2004-04-01 Johns Hopkins University School Of Medicine Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
GB0225279D0 (en) 2002-10-30 2002-12-11 Celltech R&D Ltd Biological products
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US20060257381A1 (en) 2003-06-27 2006-11-16 Keiya Ozawa Method for transplanting lymphohematopoietic cells into mammal
US7435596B2 (en) * 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20050113564A1 (en) * 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
ES2653570T3 (es) 2004-05-27 2018-02-07 The Trustees Of The University Of Pennsylvania Células presentadoras de antígeno artificiales novedosas y usos de las mismas
US7618817B2 (en) * 2004-07-10 2009-11-17 Fox Chase Cancer Center Genetically modified human natural killer cell lines
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
GB0426903D0 (en) 2004-12-08 2005-01-12 Alexis Biotech Ltd Complexes and methods
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US20080299137A1 (en) 2005-10-28 2008-12-04 Novo Nordisk A/S Fusion Proteins That Bind Effector Lymphocytes And Target Cells
US20070160578A1 (en) 2005-12-14 2007-07-12 The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
US7932055B2 (en) 2006-06-22 2011-04-26 Novo Nordisk A/S Soluble heterodimeric CD94/NKG2 receptors fusion proteins
PT2856876T (pt) 2007-03-30 2018-03-28 Memorial Sloan Kettering Cancer Center Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos
US20110059137A1 (en) 2008-03-21 2011-03-10 H. Lee Moffitt Cancer Center And Research Institutute, Inc Chemokine gene-modified cells for cancer immunotherapy
PL3006459T3 (pl) 2008-08-26 2022-01-17 City Of Hope Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu
CN101684456A (zh) 2008-09-28 2010-03-31 江门罗森生物制药有限公司 一种体外培养条件下扩增人nk细胞的方法
WO2010071836A1 (en) 2008-12-19 2010-06-24 Inserm Il-15 mediated nk and t cell maturation
US8469717B2 (en) 2009-03-20 2013-06-25 EBM Corporation Blood vessel model for medical training and method for manufacturing same
JP2012521215A (ja) 2009-03-26 2012-09-13 アヴァリス・アクチエボラーグ Ｎｋ細胞の増殖
NZ714757A (en) 2009-08-14 2018-07-27 Us Gov Health & Human Services Use of il-15 to increase thymic output and to treat lymphopenia
US20130058921A1 (en) 2009-10-30 2013-03-07 Frits VAN RHEE Use of autologous effector cells and antibodies for treatment of multiple myeloma
EP2493485A1 (en) 2009-10-30 2012-09-05 University Of Arkansas For Medical Science Use of autologous effector cells for treatment of multiple myeloma
US8772459B2 (en) 2009-12-02 2014-07-08 Imaginab, Inc. J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use
EP2519239B1 (en) 2009-12-29 2017-03-08 Gamida Cell Ltd. Methods for enhancing natural killer cell proliferation and activity
EP2576815B1 (en) 2010-06-04 2018-02-14 Biomérieux Method for the prognosis of colorectal cancer
WO2012009422A1 (en) 2010-07-13 2012-01-19 Anthrogenesis Corporation Methods of generating natural killer cells
US9212229B2 (en) 2010-09-08 2015-12-15 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Chimeric antigen receptors with an optimized hinge region
WO2012136231A1 (en) * 2010-09-08 2012-10-11 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
CN105017429B (zh) 2010-09-21 2021-04-06 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
US9844593B2 (en) 2010-11-22 2017-12-19 Innate Pharma Sa Methods for treatment of recurrent hematological malignancies
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20120321666A1 (en) 2011-05-23 2012-12-20 Cooper Laurence J N T cell therapy for b cell lymphoma
SG11201400527XA (en) 2011-09-16 2014-04-28 Univ Pennsylvania Rna engineered t cells for the treatment of cancer
US20140255363A1 (en) 2011-09-16 2014-09-11 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
BR112014007029A2 (pt) 2011-09-23 2017-04-11 Bluebird Bio Inc métodos aperfeiçoados de terapia gênica
ITMO20110270A1 (it) 2011-10-25 2013-04-26 Sara Caldrer Una cellula effettrice modificata per il trattamento di neoplasie esprimenti il disialonganglioside gd2
WO2013074916A1 (en) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
CN103294374A (zh) 2012-02-23 2013-09-11 中兴通讯股份有限公司 一种触摸屏解锁方法及装置
CN104750498B (zh) 2012-02-24 2018-12-18 青岛海信电器股份有限公司 一种控制鼠标模块的方法及电子设备
WO2014005072A1 (en) 2012-06-28 2014-01-03 University Of Central Florida Research Foundation, Inc. Methods and compositions for natural killer cells
EP2872617A4 (en) 2012-07-13 2015-12-09 Univ Pennsylvania EPITOP SPREADING IN CONNECTION WITH CAR T CELLS
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
WO2014022826A2 (en) 2012-08-03 2014-02-06 Icahn School Of Medicine At Mount Sinai Biomarker associated with risk of melanoma reoccurrence
US9365641B2 (en) 2012-10-01 2016-06-14 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
WO2014055413A2 (en) 2012-10-02 2014-04-10 Bloodcenter Research Foundation A method of providing cellular therapy using modified natural killer cells or t lymphocytes
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
WO2014099671A1 (en) 2012-12-20 2014-06-26 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
LT2956175T (lt) 2013-02-15 2017-12-11 The Regents Of The University Of California Chimerinis antigeno receptorius ir jo panaudojimo būdai
KR20210108497A (ko) 2013-02-26 2021-09-02 메모리얼 슬로안 케터링 캔서 센터 면역치료용 조성물 및 방법
CN103113470B (zh) 2013-02-27 2015-04-22 四川大学 靶向人egfr的基因工程化淋巴细胞及其制备方法和用途
EP2964753B1 (en) 2013-03-07 2018-04-25 Baylor College of Medicine Targeting cd138 in cancer
EP2968601A1 (en) 2013-03-10 2016-01-20 Baylor College Of Medicine Chemotherapy-resistant immune cells
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
CN105246504A (zh) 2013-03-15 2016-01-13 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
WO2014172584A1 (en) 2013-04-17 2014-10-23 Baylor College Of Medicine IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER
KR102238226B1 (ko) 2013-05-14 2021-04-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용
WO2014201021A2 (en) 2013-06-10 2014-12-18 Dana-Farber Cancer Institute, Inc. Methods and compositions for reducing immunosupression by tumor cells
WO2015058018A1 (en) 2013-10-17 2015-04-23 National University Of Singapore Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
AU2014342020C1 (en) 2013-10-31 2019-09-05 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-T effector cells, and uses thereof
WO2015075468A1 (en) 2013-11-21 2015-05-28 Ucl Business Plc Cell
AU2014368383B2 (en) 2013-12-20 2020-01-16 Cellectis Method of engineering multi-input signal sensitive T cell for immunotherapy
HRP20201906T1 (hr) 2013-12-20 2021-04-02 Fred Hutchinson Cancer Research Center Označene kimerne efektorske molekule i njihovi receptori
EP3626748A1 (en) 2014-01-13 2020-03-25 Stephen J. Forman Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
US20170015975A1 (en) 2014-02-10 2017-01-19 Nvigen, Inc. Cell modulation nanocomposition, and methods of use
KR102375998B1 (ko) 2014-02-14 2022-03-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 항원 수용체 및 제조방법
ES2857226T3 (es) 2014-03-15 2021-09-28 Novartis Ag Receptor de antígeno quimérico regulable
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
WO2015154012A1 (en) 2014-04-03 2015-10-08 Memorial Sloan-Kettering Cancer Center Clonogenic natural killer (nk) cell populations and methods of producing and using such populations
SI3689899T1 (sl) 2014-04-25 2022-01-31 2Seventy Bio, Inc. MND promotor kimeričnih antigenskih receptorjev
EP3143134B1 (en) 2014-05-15 2020-10-28 National University of Singapore Modified natural killer cells and uses thereof
NZ726989A (en) 2014-06-06 2020-08-28 Bluebird Bio Inc Improved t cell compositions
KR20170018450A (ko) 2014-06-18 2017-02-17 케모테라포이티쉐스 포르슝스인스티투트 게오르크-스파이어-하우스 세포 치료제로서의 car-발현 nk-92 세포
MX2017000646A (es) 2014-07-15 2017-04-27 Juno Therapeutics Inc Celulas geneticamente modificadas para terapia celular adoptiva.
JP6919118B2 (ja) 2014-08-14 2021-08-18 ノバルティス アーゲー ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
EP3186284B1 (en) 2014-08-28 2022-04-06 BioAtla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
US10961506B2 (en) 2014-09-04 2021-03-30 Stemcell Technologies Inc. Soluble antibody complexes for T cell or NK cell activation and expansion
MX2017003062A (es) 2014-09-09 2017-12-14 Unum Therapeutics Receptores quimericos y usos de los mismos en terapia inmune.
UA123764C2 (uk) 2014-09-15 2021-06-02 МОЛМЕД СпА Химерний рецептор антигену та його застосування при лікуванні пухлин, які експресують cd44
US20170246217A1 (en) 2014-09-16 2017-08-31 Funndación Pública Andaluza Progreso y Salud Use of cord blood plasma to treat nk cell-mediated diseases and ifn-γ mediated diseases
MA41538A (fr) 2014-10-17 2017-12-26 Baylor College Medicine Cellules immunitaires bipartites et tripartites de signalisation
EP3223856B1 (en) 2014-10-27 2025-09-24 University of Central Florida Research Foundation, Inc. Methods and compositions for natural killer cells
EP3215534B1 (en) 2014-11-05 2020-04-15 Board of Regents, The University of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
MA40318A (fr) 2014-11-05 2017-09-13 Juno Therapeutics Inc Procédés de transduction et de traitement de cellules
HK1243441A1 (zh) 2014-11-05 2018-07-13 Board Of Regents, The University Of Texas System 基因修饰的免疫效应细胞和用於扩增免疫效应细胞的工程化细胞
EP3018200A1 (en) 2014-11-07 2016-05-11 Fondazione Matilde Tettamanti e Menotti de Machi Onlus Improved method for the generation of genetically modified cells
WO2016075612A1 (en) 2014-11-12 2016-05-19 Rinat Neuroscience Corp. Inhibitory chimeric antigen receptors
KR20170090506A (ko) 2014-12-19 2017-08-07 다나-파버 캔서 인스티튜트 인크. 키메라 항원 수용체 및 이의 사용 방법
CN107249604A (zh) 2014-12-31 2017-10-13 人类起源公司 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
WO2016109661A1 (en) 2014-12-31 2016-07-07 Anthrogenesis Corporation Natural killer cells and uses thereof
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
US10377988B2 (en) 2015-01-23 2019-08-13 Musc Foundation For Research Development Cytokine receptor genes and the use thereof to enhance therapy
MA41433A (fr) 2015-01-26 2017-12-05 Baylor College Medicine Cellules immunitaires universelles pour l'immunothérapie anticancéreuse
CN113862292B (zh) 2015-01-29 2024-12-27 明尼苏达大学董事会 嵌合抗原受体、组合物以及方法
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
ES2926384T3 (es) 2015-02-06 2022-10-25 Nat Univ Singapore Métodos para mejorar la eficacia de células inmunitarias terapéuticas
AU2016214301B2 (en) 2015-02-06 2022-05-19 Cellectis Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
CN107531805A (zh) 2015-03-05 2018-01-02 弗雷德哈钦森癌症研究中心 免疫调节融合蛋白及其用途
GB201503742D0 (en) 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
EP3064507A1 (en) 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
EP3270936A4 (en) 2015-03-17 2018-08-08 Chimera Bioengineering Inc. Smart car devices, de car polypeptides, side cars and uses thereof
CN107614008A (zh) 2015-03-20 2018-01-19 蓝鸟生物公司 载体制剂
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
WO2016164370A1 (en) 2015-04-06 2016-10-13 Ohio State Innovation Foundation Egfr-directed car therapy for glioblastoma
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
WO2016172537A1 (en) 2015-04-23 2016-10-27 The Trustees Of The University Of Pennsylvania Compositions to disrupt protein kinase a anchoring and uses thereof
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
GB201507108D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507104D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507115D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507119D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507111D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
US20190031759A1 (en) 2015-04-30 2019-01-31 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
CA3021226A1 (en) 2015-05-11 2016-11-17 University Health Network Method for expansion of double negative regulatory t cells
CN107847583A (zh) 2015-05-28 2018-03-27 阿尔莫生物科技股份有限公司 用于治疗癌症的聚乙二醇化白细胞介素‑10
KR20230148387A (ko) 2015-05-28 2023-10-24 카이트 파마 인코포레이티드 T 세포 요법을 위한 진단 방법
WO2016196388A1 (en) 2015-05-29 2016-12-08 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
WO2016197108A1 (en) 2015-06-05 2016-12-08 Board Of Regents, The University Of Texas System Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type
KR20240013282A (ko) 2015-06-10 2024-01-30 이뮤너티바이오, 인크. 암을 치료하기 위한 변형된 nk-92 세포
US11655452B2 (en) 2015-06-25 2023-05-23 Icell Gene Therapeutics Inc. Chimeric antigen receptors (CARs), compositions and methods of use thereof
HK1255637A1 (zh) 2015-06-29 2019-08-23 The Johns Hopkins University 免疫检查点嵌合受体疗法
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
WO2017023859A1 (en) 2015-07-31 2017-02-09 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting cd56 and uses thereof
EP4400517A3 (en) 2015-08-04 2024-10-16 Xyphos Biosciences Inc. Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands, and non-natural nkg2d ligands that bind non-natural nkg2d receptors
ES3020458T3 (en) 2015-08-07 2025-05-22 Imaginab Inc Antigen binding constructs to target molecules
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
GB201514874D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Cell
WO2017032777A1 (en) 2015-08-24 2017-03-02 Cellectis Chimeric antigen receptors with integrated controllable functions
EP3138905A1 (en) 2015-09-04 2017-03-08 Miltenyi Biotec GmbH Method for natural killer cell expansion
WO2017058753A1 (en) 2015-09-28 2017-04-06 Trustees Of Dartmouth College Chimeric antigen receptor, regulatory cells and methods of use
WO2017058752A1 (en) 2015-09-28 2017-04-06 Trustees Of Dartmouth College Chimeric antigen receptor anti-inflammatory cells and methods of use
BR112018009129A2 (pt) 2015-11-04 2019-02-26 J. PRICEMAN Saul receptores de antígeno quimérico que visam her2
MA44314A (fr) 2015-11-05 2018-09-12 Juno Therapeutics Inc Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
CN107109363A (zh) 2015-11-09 2017-08-29 张明杰 增强对异常细胞杀伤力的方法和药物组合物
WO2017096329A1 (en) 2015-12-03 2017-06-08 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
JP6853514B2 (ja) 2015-12-27 2021-03-31 国立大学法人東海国立大学機構 炎症性サイトカインの産生が抑制されるキメラ抗原受容体遺伝子改変リンパ球
CA3010236A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
AU2017244108B2 (en) 2016-03-29 2021-03-18 University Of Southern California Chimeric antigen receptors targeting cancer
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
CN110358736B (zh) 2016-05-20 2023-07-07 杭州朔溪生物医药有限公司 一种修饰的k562细胞、其制备方法及nk细胞培养组合物
US11787848B2 (en) 2016-06-08 2023-10-17 Precigen, Inc. CD33 specific chimeric antigen receptors
CN105985931A (zh) 2016-06-21 2016-10-05 黑龙江天晴干细胞股份有限公司 一种nk细胞体外扩增组合物及nk细胞扩增方法
CA2937157A1 (en) 2016-07-25 2018-01-25 Ucl Business Plc Protein-based t-cell receptor knockdown
SG11201810871WA (en) 2016-07-25 2019-01-30 Us Health Methods of producing modified natural killer cells and methods of use
CN108148862B (zh) 2016-12-05 2019-03-08 上海优卡迪生物医药科技有限公司 一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用
CN110249046A (zh) 2016-12-05 2019-09-17 朱诺治疗学股份有限公司 用于过继细胞疗法的工程化细胞的产生
JP6971319B2 (ja) 2016-12-28 2021-11-24 グリーン・クロス・ラブ・セル・コーポレイション キメラ抗原受容体及びそれを発現するナチュラルキラー細胞
EP3601537A4 (en) 2017-03-27 2021-01-13 National University of Singapore STIMULATING CELL LINES FOR EX VIVO EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS
SG11201908492PA (en) 2017-03-27 2019-10-30 Nat Univ Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
KR20200035304A (ko) 2017-08-10 2020-04-02 싱가포르국립대학교 T 세포 수용체-결핍 키메라 항원 수용체 t-세포 및 이의 사용 방법
CN109554348A (zh) 2017-09-27 2019-04-02 亘喜生物科技（上海）有限公司 可诱导分泌抗cd47抗体的工程化免疫细胞
EP3697425A1 (en) 2017-10-18 2020-08-26 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Methods and compounds for improved immune cell therapy
CN107827990B (zh) 2017-10-30 2020-07-10 河北森朗生物科技有限公司 一种多肽、编码其的核酸、其修饰的t淋巴细胞及其应用
CN118256563A (zh) 2017-11-10 2024-06-28 北京卡替医疗技术有限公司 一种扩增免疫细胞的方法
CN109971712B (zh) 2017-12-28 2023-06-20 上海细胞治疗研究院 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
WO2019127215A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
CN111801348A (zh) 2018-02-09 2020-10-20 新加坡国立大学 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
WO2019155286A2 (en) 2018-02-09 2019-08-15 National University Of Singapore Adhesion receptor constructs and uses thereof in natural killer cell immunotherapy
WO2019169290A1 (en) 2018-03-02 2019-09-06 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
WO2019178259A2 (en) 2018-03-14 2019-09-19 Celledit Llc Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy
KR20200138741A (ko) 2018-04-02 2020-12-10 내셔널 유니버시티 오브 싱가포르 면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화
JP7560882B2 (ja) 2018-08-29 2024-10-03 ナショナル ユニヴァーシティー オブ シンガポール 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法
JP7520818B2 (ja) 2018-09-13 2024-07-23 ンカルタ・インコーポレイテッド 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法
CN111088231A (zh) 2018-10-24 2020-05-01 艾生命序公司 Pd-l1抗体分泌的抗间皮素car-t细胞肿瘤免疫治疗
AU2019385873A1 (en) 2018-11-26 2021-06-03 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
US20220233593A1 (en) 2019-06-04 2022-07-28 Nkarta, Inc. Combinations of engineered natural killer cells and engineered t cells for immunotherapy
CA3146987A1 (en) 2019-07-17 2021-01-21 National University Of Singapore Functional binders synthesized and secreted by immune cells
KR20220038439A (ko) 2019-07-31 2022-03-28 엔카르타, 인크. 자연 살해 세포의 향상된 증폭 및 세포 독성을 위한 방법 및 조성물
US20230028399A1 (en) 2020-01-13 2023-01-26 Nkarta, Inc. Bcma-directed cellular immunotherapy compositions and methods
US12012458B2 (en) 2020-06-12 2024-06-18 Nkarta, Inc. Genetically modified natural killer cells for CD70-directed cancer immunotherapy
JP2023539361A (ja) 2020-09-02 2023-09-13 ンカルタ・インコーポレイテッド 操作されたナチュラルキラー細胞の増殖および細胞毒性の増強およびその使用
US20230390392A1 (en) 2022-03-07 2023-12-07 Nkarta, Inc. Multiplex gene edited cells for cd70-directed cancer immunotherapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Christiane Sahm等.Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor.《Cancer Immunol Immunother》.2012,第61卷(第9期), *
Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor;Christiane Sahm等;《Cancer Immunol Immunother》;20120205;第61卷(第9期);第1451-1461页 *
登录号NM_172175.2;Doyle,S.L.等;《NCBI_GenBank》;20131222;序列信息 *

Also Published As

Publication number Publication date
AU2023214279A1 (en) 2023-08-31
WO2015174928A1 (en) 2015-11-19
AU2015259877A1 (en) 2016-11-17
US11560548B2 (en) 2023-01-24
US12264335B2 (en) 2025-04-01
JP7141644B2 (ja) 2022-09-26
DK3143134T3 (da) 2021-01-04
KR102211120B1 (ko) 2021-02-03
CN112175911A (zh) 2021-01-05
PT3143134T (pt) 2020-12-04
US20170073638A1 (en) 2017-03-16
EP3143134A1 (en) 2017-03-22
AU2015259877B2 (en) 2021-02-25
US10428305B2 (en) 2019-10-01
KR20210014210A (ko) 2021-02-08
JP2020141677A (ja) 2020-09-10
SG11201609118RA (en) 2016-11-29
JP2017515506A (ja) 2017-06-15
US20250320457A1 (en) 2025-10-16
JP6694875B2 (ja) 2020-05-20
CN106459914B (zh) 2020-11-06
CA2948462A1 (en) 2015-11-19
ES2839089T3 (es) 2021-07-05
JP2022184852A (ja) 2022-12-13
AU2021203276A1 (en) 2021-06-17
US20190376037A1 (en) 2019-12-12
AU2021203276B2 (en) 2023-05-25
EP3805371A1 (en) 2021-04-14
KR20240123416A (ko) 2024-08-13
US10774311B2 (en) 2020-09-15
JP7421194B2 (ja) 2024-01-24
US20230220343A1 (en) 2023-07-13
AU2023214279B2 (en) 2025-08-28
KR20170000388A (ko) 2017-01-02
CN106459914A (zh) 2017-02-22
EP3143134B1 (en) 2020-10-28
US20200407686A1 (en) 2020-12-31
EP3143134A4 (en) 2017-10-18
JP2024045158A (ja) 2024-04-02

Similar Documents

Publication Publication Date Title
JP7421194B2 (ja) 改変ナチュラルキラー細胞及びその使用
JP7046112B2 (ja) 改変された造血幹／前駆細胞及び非エフェクターｔ細胞、そしてそれらの用途
US9650428B2 (en) Methods and compositions for treating cancer
CN105408473B (zh) 工程化嵌合抗原受体(car)t细胞的人应用
CN111247242A (zh) 嵌合抗原受体(CARs)、组合物及其使用方法
TW201809271A (zh) 用於轉導淋巴球及調節其活性之方法及組合物
US20240084256A1 (en) Method for culturing cord blood-derived natural killer cells using transformed t-cells
HK40042905A (en) Modified natural killer cells and uses thereof
HK1233307A1 (en) Modified natural killer cells and uses thereof
HK40042905B (zh) 经修饰的自然杀伤细胞及其用途
HK1233307B (zh) 经修饰的自然杀伤细胞及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40042905

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant